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Protein C inhibitor (PCI) is a heparin-binding plasma 
serine proteinase inhibitor (serpin) which is thought to 
be a physiological regulator of activated protein C. We 
are using  recombinant PC1 (rPCI) to study structural 
determinants of target proteinase specificity. A cDNA 
encoding  full-length PC1 has been  expressed as a fully 
active proteinase inhibitor using Autographa califor- 
nica nuclear polyhedrosis virus (baculovirus).  rPCI  was 
expressed  maximally 4 days after infection and could  be 
expressed either in Sf9 or High-FiveTM  cells.  rPCI  bound 
heparin and was  conveniently purified with heparin- 
Sepharose (eluting >0.5 M NaCl). The rPCI  formed so- 
dium  dodecyl  sulfate-polyacrylamide gel electrophore- 
sis-stable complexes  with  thrombin and activated 
protein C (APC).  The inhibitory properties of wild-type 
rPCI and plasma-derived PC1 are essentially the same 
either in the absence or presence of heparin with  throm- 
bin, APC, trypsin, and urokinase. 
The residues PheSSs-Arg5S4-SerSSS (P2-P1-Pl’) constitute 
part of the reactive site loop of PC1 with the Arg-Ser 
peptide bond being cleaved by the proteinase. Using 
site-directed mutagenesis we studied the contribution 
of the reactive site FRS for proteinase inhibition in 
rPCI.  Changing the P1 residue Arg“ + Met generated a 
reactive site similar to a,-proteinase inhibitor which 
was a much poorer inhibitor of thrombin, APC, trypsin, 
and urokinase.  Changing the P2 residue PheSSS + Gly 
generated a mutant with a reactive site like antithrom- 
bin  which  was better at inhibiting thrombin or uroki- 
nase, but was much less active with APC or trypsin. 
Changing the P1’ residue SersSs + Met generated a reac- 
tive site like plasminogen activator inhibitor-1 and this 
protein inhibits all the proteinases essentially like wild- 
type  rPCI.  These results show the importance of PCI’s 
Phe3ss (P2) and Arg” (Pl) in target proteinase specific- 
ity, and they further support the concept of reactive site 
sequences determining serpin function. 
Protein C inhibitor (PCI)’ is a plasma glycoprotein which is 
a member of the  serine  proteinase  inhibitor  (serpin)  superfam- 
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ily of proteins (1-61, whose prototype is  a,-proteinase  inhibitor 
(7, 8). PC1 (also known as plasminogen activator  inhibitor-3) 
can be further classified as a heparin-binding  serpin  (1, 4, 5 ,  
9, lo), along  with  the  proteinase  inhibitors  antithrombin  (his- 
torically  known as  antithrombin 111), heparin cofactor 11, and 
protease nexin-I (for a review, see Refs. 5 ,  6,  and 11-13 and 
references  cited therein).  Heparin  and some other glycosamin- 
oglycans act to increase  the  rate of proteinase inhibition by 
these  serpins,  in some cases  as  much  as  several thousand-fold. 
An important biological function of PC1 and  other  serpins is 
the  regulation of the  proteinases involved in  hemostasis (14, 
15). Thrombin and  activated  protein C (APC) are believed to 
be partially regulated by PC1 (16-19). Direct evidence for a 
PC1 function  from  a patient deficiency has  not been clinically 
documented, although in  vivo animal model clearance studies 
have clearly  shown that PC1 inhibits APC (20-22). Other 
plasma proteins, including a,-macroglobulin and  the  serpins 
a,-proteinase inhibitor and a,-antiplasmin, can inhibit APC 
(23-261, whereas known thrombin  inhibitors include a,-mac- 
roglobulin and  three  other  plasma  serpins:  antithrombin,  hep- 
arin cofactor 11, and a,-proteinase inhibitor. Thus, there is 
some redundancy of plasma  proteinase  inhibitors  to  react with 
their  various  putative  target  proteinases. 
The  reactive  site Arg354-Ser355 peptide bond located near  the 
carboxyl terminus of PC1 (termed  the P1-P1’ bond using  the 
nomenclature of Schechter and Berger (27)) reacts with the 
active site ofAPC and  thrombin  to form an essentially  irrevers- 
ible  bimolecular complex (1,2).  The  reactive  site P1 Arg residue 
of PC1 is presumably  important for proteinase recognition but 
alone  probably does not  determine specificity. Additionally, PC1 
inhibits  other  proteinases,  including  kallikrein, factors Xa and 
XIa, urokinase,  tissue plasminogen  activator, prostate specific 
antigen,  trypsin,  and chymotrypsin (1, 3, 28-33). This broad 
proteinase inhibition pattern presents a problem in under- 
standing the physiological importance of PCI. Interestingly, 
antithrombin which has the same Arg-Ser-reactive site se- 
quence (8 )  inhibits a wide range of proteinases, including 
thrombin, factor Xa, kallikrein, and trypsin, but does not 
readily  inhibit APC. APC inhibition by PCI-heparin (k, of - 1 x 
lo6 M” min”  (4)) is 1-2 orders of magnitude lower than  other 
well characterized  serpin-proteinase  inhibition  reactions  in  the 
absence or presence of glycosaminoglycans. Some examples of 
other  serpin-proteinase  inhibition  reactions include: anti- 
thrombin-heparin-thrombin ( k ,  of -1 x log M” min”), heparin 
cofactor II-heparin-thrombin ( k ,  of -4 x 10’ M - ~  min-l), plas- 
minogen activator  inhibitor-1 (PAI-1)-tissue  plasminogen acti- 
vator ( k ,  of -3 x 10’ M-, min-l), and  a,-antiplasmin-plasmin (k, 
of -4 x lo7 M - ~  min-l) (5434,351. This may  be due  to evolution- 
ary  constraints which allows AFT “physiological time” for ex- 
pression of its  anticoagulant action  (36). 
tor; APC, activated  protein C; PAI-1, plasminogen activator  inhibitor-1; 
PAGE, polyacrylamide gel electrophoresis; CAPS, 3-(cyclohexylamino)- 
propanesulfonic acid. 
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F Y S  
F R P  
ATCTTCACTTTCNNNTCGGCCCGCCTGAAC 
TTCACTTTCAGGNNNGCCCGCCTGAACTCT 
FIG. 1. Schematic  representation of the  full-length cDNAclone 
of PC1 and the strategy for mutagenesis of the  reactive site 
region. Cassette  mutagenesis  between SacI andXbaI  was  performed  to 
create the reactive site mutants in the P2, P1, and P1’ amino acid 
position using  these  designed  synthetic oligonucleotides. The  nucleotide 
and  predicted  amino acid sequence in  these  sites  are shown for wt  rPCI 
and  the  three PC1 mutants F353G, R354M, and S355M. Positions  des- 
ignated by N in  the oligonucleotides represent  equal  mixtures of G, A, 
T, and  C  used  during oligonucelotide synthesis.  The  cassette  was cloned 
into pVL1392 to  obtain  full-length  PCI,  and  the  protein  was  expressed 
as described  under  “Experimental  Procedures.” 
The work presented  here describes the cloning, expression, 
and  characterization of wild-type recombinant  protein C inhibi- 
tor (wt  rPCI)  in a Baculovirus  expression system. We have  used 
site-directed mutagenesis to examine the  importance of the P1, 
Pl’,  and  P2 reactive site  residues  in  the  proteinase reactivity of 
rPCI  with APC, thrombin,  trypsin,  and urokinase. 
EXPERIMENTAL PROCEDURES 
Expression of Full-length rPCI-Wild-type human PC1 cDNA con- 
taining  the  signal  peptide  sequence  (kindly provided by Dr. Joost C. M. 
Meijers,  Department of Hematology, Utrecht  University  Hospital, 
Utrecht,  The  Netherlands)  was  subcloned  into  the  baculovirus  expres- 
sion vector pVL1392 (Invitrogen) using the restriction endonuclease 
sites EcoRI 5’  and BamHI 3‘ (Fig. 1) (all restrictions enzymes pur- 
chased from Promega).  Transfer vector (pVL1392) containing wt rPCI 
and  each of the engineered mutations were cotransfected with DNA 
from Autographa  californica  nuclear  polyhedrosis  virus (AcNPV) into 
insect  host  cells  (Sf9,  Spodoptera  frugiperda  cells,  in  complete Grace’s 
medium) using kits from Invitrogen (wt rPCI and F353G rPCI) or 
PharMingen (R354M, S355M, and S355V rPCIs). Individual plaques 
were  purified  and  screened for PC1 production by immunoblot. Recom- 
binant  viral  stocks  were  amplified  and  used  to  infect  High-FiveTM cells
(Invitrogen)  grown  in  serum-free  medium  (Excell,  JRH Biosciences) for 
protein  production. 
Expressed  proteins  were  purified  4  days  post-infection by incubating 
the infected  medium (50 ml of medium  from two T-150 flasks of conflu- 
ent High-FiveTM  cells)  with 0.5 ml of heparin-Sepharose  beads  (Phar- 
macia Biotech Inc.)  equilibrated  in 20 mM HEPES, 150 mM NaC1,  0.1% 
polyethylene glycol, 0.02% NaN,, pH 7.4 (HNPN).  The  beads  were col- 
lected by gentle  centrifugation,  washed twice with  HNPN, once with 
HNPN containing 0.25 M NaCI, and then the rPCI was eluted with 
HNPN  containing  1.0 M NaC1. The  protein  was  then  dialyzed  against 
HNPN. Average yield of rPCI  was  in  the  range of  170-300 pg of protein. 
Reactive Site Region Mutagenesis of rPCI-A fragment of the PC1 
cDNA was cloned into M13mp19 using SacI and XbaI. Uracil-rich 
single-stranded DNA was  prepared  and  annealed  to specific oligonucle- 
otides  designed  to  generate  mutations  in  the  reactive  site  region of PC1 
(Fig. 1) using  the  method of Kunkel  (37).  Individual  plaques  were  pu- 
rified  and  sequenced  to c nfirm the introduced  nucleotide  substitutions. 
Each  generated  mutation  was cloned into pVL1392 usingXbaI  and SacI 
to  generate  full-length PC1 containing the single engineered change. 
The  transfer vector was  sequenced before transfection  to confirm that 
the desired  mutation  was  present. 
PCI Immunodetection-A direct  enzyme-linked  immunosorbent  as- 
say  using a rabbit  anti-PC1  antiserum (1:5000 dilution)  and  goat  anti- 
rabbit  IgG  linked  with  alkaline  phosphatase  (1:2000  dilution,  Sigma) 
was  used  to  measure  rPCI  concentrations.  Purified  human  plasma PC1 
was  used  as a standard.  Samples  were  incubated  overnight  in a 96-well 
microtiter  plate a t  a final volume of 100 pl. The  plate  was  then blocked 
with  1%  milk  in  TBST  (10 mM Tris-HCI, 150 mM NaCl,O.05’% Tween 20, 
pH  7.5).  Primary  and  secondary  antibodies  diluted  in  TBST  were  added 
for 3 h  each at room temperature,  with  TBST  washes  between  incuba- 
tions. Bound antibody was quantitated using 1 mg/ml p-nitrophenyl 
phosphate  (Sigma)  in  AP  buffer (0.1 M Tris, 0.1 M NaC1,5 mM MgCl,, pH 
9.5)  and  the  absorbance  change  measured on a V,, microplate  reader 
(Molecular Devices). There  was an excellent  correlation  between PC1 
concentration  determined by enzyme-linked  immunosorbent  assay  and 
that calculated by titration  with  active  site-titrated  thrombin. However, 
for internal  consistency  and  due to  the  variable  activity of some of the 
rPCI  mutants,  the enzyme-linked  immunosorbent  assay  was  used to  
determine  rPCI  concentrations. 
Immunoblots  were  performed by first  subjecting  samples  to  sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (38) fol- 
lowed by transfer  to  an  Immobilon-P  filter (polyvinylidene difluoride, 
Millipore). The filter was blocked in TBST-milk and incubated over- 
night  with  a  mouse monoclonal antibody  to PC1 (1:lOO dilution).  Goat 
anti-mouse IgG linked  to  alkaline  phosphatase  was  used as a secondary 
antibody, and  bands  were  detected  using  0.33 mg/ml nitro  blue  tetra- 
zolium and 0.12 mg/ml 5-bromo-4-chloro-3-indolyl phosphate in AP 
buffer. 
Protein Sequencing-Approximately 60 pmol of rPCI  was  subjected 
to  SDS-PAGE taking precautions to  minimize protein oxidation that 
may block the  amino  terminus  (39).  The  proteins  were  transferred  onto 
Immobilon-P  in  buffer  containing  10 mM CAPS, 10% methanol,  pH 11 a t  
0.3  amps for 20 min.  The  blot  was  stained  with Coomassie Brilliant 
Blue R-250, destained,  and  washed  extensively  to remove any  residual 
Tris or glycine. The  rPCI  band  was excised with  a  sterile  scalpel  and 
subjected to  automated  amino-terminal  sequencing  using an A B 1  model 
470A sequencer  (Howard  Hughes Medical Institute,  Duke  University 
Medical Center,  Durham,  NC). 
Deglycosylation Reaction-N-Linked carbohydrate  was cleaved using 
peptide-N-glycosidase F (Oxford GlycoSystems). Plasma PC1 and  rPCI 
were boiled for 2  min  in a supplied buffer containing 0.5% SDS  and 5% 
P-mercaptoethanol. Upon cooling the solution  was  made 2% in  Triton 
X-100 and  the glycosidase added  overnight a t  room temperature.  The 
sample  was  then  subjected to  SDS-PAGE and  immunoblotted  using  a 
mouse monoclonal antibody  to  PCI. 
Proteinase  Inhibition Assays-Plasma PC1 was  purified as previously 
described  (33)  with an  additional  step of immunoafflnity  chromatogra- 
phy on an anti-PC1 monoclonal antibody  column.  Thrombin  was  pre- 
pared as detailed  previously  (40).  Trypsin  was  purchased from Calbio- 
chem,  and  a conversion factor of 2972 unitsimg  was  used.  Urokinase 
was  purchased from American  Diagnostica  and  a conversion factor of 
80,000 unitslmg  was  used.  Assays  were  performed at room temperature 
in  HNPN  in  the  presence of 2 mg/ml bovine serum  albumin.  For  assays 
in  the absence of heparin,  0.1 mg/ml Polybrene  (Sigma)  was  also  in- 
cluded in  the buffer. Chromogenic substrates for the  proteinases  were: 
Lys-carbobenzoxy-Pro-Arg-p-nitroanilide (Spectrozyme  PCa,  American 
Diagnostica) for APC; carbobenzoxy-L-(g)Glu(a-t-BuO)-Gly-Argp-ni- 
troanilide  (Spectrozyme UK, American  Diagnostica) for urokinase; to- 
syl-Gly-Pro-Arg-p-nitroanilide (Boehringer Mannheim) for thrombin 
and trypsin. Unbleached crude heparin was obtained from Diosynth 
(Oss, The  Netherlands). 
Second order  inhibition  rate  constants (k , ,  M-, min”)  were  measured 
in  triplicate on at least  two  separate  preparations of each  serpin.  Each 
rate  (reported  as  mean * S.D.)  was  measured from two to  eight  times 
under  pseudo-first  order  reaction  conditions a described previously (4, 
5, 41).  Protein  concentrations for the  various  serpin-proteinase  inhibi- 
tion reactions shown in Table I were: 0.5 nM thrombin, 5 nM (r)PCI, 
antithrombin,  and  a,-proteinase  inhibitor, 1 pg/ml heparin; 1 nM APC, 
10 nM (r)PCI,  antithrombin,  and  a,-proteinase  inhibitor,  10 pg/ml hep- 
arin (rPCI’s,  antithrombin,  and  a,-proteinase  inhibitor), or 100 pg/ml 
heparin (plasma PCI); 5 nM urokinase, 100 nM (r)PCI, antithrombin, 
and  a,-proteinase  inhibitor,  10 pg/ml heparin;  and 1 nM trypsin,  10 nM 
(r)PCI, antithrombin, and a,-proteinase inhibitor, 10 pg/ml heparin. 
Reaction volumes were 50 PI, and the reaction was started by the 
addition of 5 p1  of proteinase. 50-100 p1  of chromogenic substrate con- 
taining 1 mg/ml Polybrene  was  added  to block heparin. Following color 
development, the  assay  was  terminated by adding 50 pl of 50% acetic 
acid and the absorbance a t  405 measured using the V, microplate 
reader. Rate constants were calculated using the equation k ,  = (-ln 
a)/t[Il,  where a is  residual  proteinase activity, t is  time  and  [I]  is  the 
serpin  concentration  (4,  5,411. All inhibition  assays  were  performed by 
time course analysis to  ensure  that  the kinetic  parameters  were fol- 
lowed and that at least 50% proteinase inhibition was achieved for 
calculation of inhibition  rates. 
To measure  optimum  heparin  concentrations for (r)PCI  inhibition of 
thrombin  and APC, the  same  concentrations of serpin  and  proteinase  as 
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FIG. 2. SDS-resistant complex formation of proteinases with 
rPCI. Thrombin  (IIa)  and APC were  incubated  with  wt  rPCI  (superna- 
tant of infected High-FiveT3‘ cells concentrated  in a Centriprep-10  tube) 
or  plasma PC1 (250 nm) in  culture  medium  with 1 pg/ml heparin for 15 
min a t  37 “C. The  samples  were boiled in SDS-PAGE sample  buffer and 
loaded onto a 108 acrylamide  gel  under  nonreducing  conditions  and 
then  visualized by immunoblot  with  a monoclonal antibody  against PC1 
2, rPCI  and APC (10 nm); lane 3, rPCI  and  thrombin (10 nM); lane 4, 
as  described under  “Experimental Procedures.”Lane 1 ,  rPCI  alone; lane 
rPCI  and APC (20 nM); lane 5, rPCI  and  thrombin  (20 nM); lane 6,  control 
P-galactosidase-infected medium  with  thrombin (20 nM); lane 7, plasma 
PC1 and  thrombin (10 nM); lane 8, plasma PC1 alone.  Migration posi- 
tions  for  molecular  size  markers:  myosin  (molecular  mass = 200 kDa), 
phosphorylase b (molecular mass = 97 kDa), bovine serum albumin 
(molecular mass = 69 kDa), ovalbumin (molecular mass = 46 kDa), 
carbonic  anhydrase  (molecular  mass = 30  kDa),  and  trypsin  inhibitor 
(molecular mass = 21.5  kDa). 
above were  used  with a final  reaction  volume of 100 pl. Final  heparin 
concentrations  varied from 0.01 to 1000 pg/ml.  Following  termination of
the reaction, the microtiter plate was subjected to centrifugation a t  
3000 rpm for 10 min  to  precipitate  heparin-Polybrene complexes which 
form a t  very  high  heparin  concentrations (4, 5, 41). 100 pl was  trans- 
ferred from each well to a fresh  microplate  and  the  absorbance a t  405 
nm  was  measured.  The  inhibition  rate (k2, M” min”)  was  calculated  for 
PC1 a t  each  heparin  concentration,  and  the  data  presented  are  mean 
values of duplicate  assays  performed  three  times  with  three  separate 
preparations of each  serpin. 
RESULTS 
Expression and Characterization of rPCI-The expression 
vector pvL1392-PC1 was  constructed as described under “Ex- 
perimental Procedures.”  Cotransfection of Sf9 cells with 
pVL1392-PC1 and baculovirus DNA resulted  in  the production 
of recombinant  viruses which were  screened by plaque assay. 
Sf9  (and High-FiveTM) cells were then infected  with the purified 
recombinant virus and supernatants were harvested. Time 
courses showed that  harvesting  the medium four days post- 
infection resulted  in  the  highest yield of immunoreactive rPCI 
(data  not shown). Wild-type rPCI  was  initially  characterized 
from the  harvested medium of the High-FiveTM cells, grown in 
serum-free medium, and  the protein further  characterized fol- 
lowing partial purification with  heparin-Sepharose. 
Thrombin and APC were incubated  with both cell-free me- 
dium containing wt rPCI and plasma PCI. Both proteinases 
formed bimolecular complexes with  wt  rPCI which were stable 
to SDS-PAGE (Fig. 2). The  apparent M, values of the  rPCI- 
proteinase complexes formed  were lower than  that of plasma 
PCI-proteinase complexes. A control with conditioned medium 
from High-FiveTm cells infected with 0-galactosidase showed no 
proteinase complex formation. Similar complexes were seen 
with the  three  rPCI  mutants  (data  not shown). 
Purified rPCI  had a lower apparent molecular  weight than 
plasma PC1 as determined by immunoblot  (Fig. 3). A  majority 
of the discrepancy was shown to be due  to incomplete N-glyco- 
sylation of the  rPCI.  Plasma  and purified rPCI were  digested 
with peptide-N-glycosidase F, resulting in both proteins mi- 
grating  with  similar  apparent molecular  weights  (Fig. 3). With 
the exception of incomplete N-glycosylation, rPCI  was  appar- 
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FIG. 3. Immunoblot of plasma rPCI and PC1 before and after 
treatment with peptide-N-glycosidase F. Plasma PC1 and wt rPCI 
were  treated  with  peptide-N-glycosidase F as  described  under  “Experi- 
mental  Procedures.” Lane 1, plasma  PCI; lane 2, rPCI; lane 3, plasma 
PC1 treated  with  peptide-N-glycosidase F; lune 4,  rPCI  treatment with 
peptide-N-glycosidase F. Migration  positions  for  molecular  size  markers 
are included. 
cycles gave  the correct amino-terminal sequence of human PC1 
(HRHHPREMKKRVEDLHV). Wild-type rPCI (and the three 
rPCI  mutants)  also  retained  heparin binding ability, eluting 
from heparin-Sepharose at >0.5 M NaCl. 
Thrombin and  APC  Inhibition by rPCI  in  the Absence and 
Presence of Heparin-Thrombin and APC inhibition time 
courses under pseudo-first order conditions were then per- 
formed  comparing wt  rPCI  to  plasma PCI. In  the absence of 
heparin, thrombin, and APC, inhibition by plasma PC1 and 
partially purified wt rPCI were essentially  indistinguishable 
(h, ,  rnin”): 1.42 2 0.67 x lo6 and 1.25 e 0.71 x lo6 for 
thrombin  with  plasma PC1 and  wt  rPCI, respectively; and 1.85 
2 0.29 x lo5 and 1.38 + 0.36 x lo5 for APC with plasma PC1 and 
wt  rPCI, respectively. Wild-type rPCI displayed a typical serpin 
heparin-dependent curve in the inhibition of both thrombin 
and APC (Fig. 4).  The  maximum  inhibition activity (h,)  was 
similar between wt  rPCI  and  plasma PCI. However, wt rPCI 
required  less  heparin  to achieve maximum  inhibitory activity. 
In  the inhibition of thrombin,  wt  rPCI  had  maximal ctivity at 
0.5 pg/ml heparin compared with 1 pg/ml for plasma PCI. With 
APC this difference was slightly greater, with maximum wt 
rPCI inhibition a t  10 pg/ml heparin compared with 100 pg/ml 
for plasma PCI. 
Inhibition of Thrombin, APC, Urokinase, and  llypsin by 
rPCI Mutants-Wild-type rPCI  and  the  three  reactive  site  mu- 
tants were tested for their ability to  inhibit four  different serine 
proteinases (Table I). Plasma PCI, antithrombin and a,-pro- 
teinase  inhibitor were  used as control serpins. Wild-type rPCI 
and  plasma PC1 showed no difference in  their  abilities  to  in- 
hibit  thrombin, APC, trypsin,  or  urokinase  in  the presence of 
optimal  heparin.  Under  the  assay conditions used,  wt  rPCI  and 
plasma PC1 are  better  inhibitors of thrombin  than of APC and 
of trypsin  than of urokinase (Table I). 
R354M rPCI which changes  the P1 residue Arg -+ Met gen- 
erated a reactive site similar to  a,-proteinase inhibitor. The 
activity of R354M rPCI  was  dramatically reduced for each pro- 
teinase compared  with wt rPCI,  but  it  was  quite  similar  and 
was not significantly different from a,-proteinase inhibitor 
with  the four proteinases  assayed (Table I). Although the h, 
value  was  half  that of wt rPCI, R354M rPCI  was  best a t  inhib- 
iting trypsin of the four proteinases tested and is a better 
inhibitor  than wt rPCI  against chymotrypsin (data not  shown). 
Changing  the  P2  residue from Phe -+ Gly, F353G rPCI, gen- 
erated a mutant  with a reactive  site  like  antithrombin which, 
relative to wt rPCI, was a better inhibitor of thrombin and 
urokinase,  but  was  less active  with APC or  trypsin (Table I). 
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The  ratio of proteinase  inhibition between wt  rPCI  and F353G 
rPCI  shifted from 25 to 396 for thrombidAPC  and from 10 to  
1.5 for trypsidurokinase, respectively. F353G rPCI was still a 
better  inhibitor of APC and  urokinase  than  was  antithrombin, 
but  antithrombin  was a  much better  inhibitor of both thrombin 
and  trypsin. 
S355M rPCI which changes the P1’ residue from Ser + Met 
generated a reactive site  similar  to PAI-1. S355M rPCI  inhibits 
thrombin, APC, trypsin, and urokinase with essentially the 
same k, values as  wt  rPCI (Table I). A second rPCI P1’ Ser 
mutant (S355V rPCI) also had  the  same k, (M-’ min”)  values as 
wt  rPCI  with  thrombin  and APC, 1.18 f 0.32 x lo7 and 6.79 2 
2.16 x lo5, respectively, which suggests  that  the P1’ position 
may not play a  crucial  role in  the activity of PCI. 
DISCUSSION 
Protein C inhibitor  has been a difficult protein to  study owing 
to  its scarcity in  plasma,  instability  during purification from 
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Frc. 4. Heparin-dependent inhibition of thrombin  and APC  by 
rPCI and plasma PCI. Thrombin (top  panel) and APC (bottom  panel) 
were  incubated  in  the  presence of a 10-fold molar  excess of wt  rPCI (0) 
and  plasma  PC1 (0) with  increasing  concentrations of heparin  as de- 
tailed  under  “Experimental  Procedures.”  The  inhibition  rate  constant 
(K,) was calculated as min” for PC1 at each heparin concentration. 
These studies were undertaken  to achieve expression of a re- 
combinant form of PC1 in order to begin to understand its 
putative  target  proteinase specificity with  particular  emphasis 
on its ability to inhibit both APC and  thrombin. Several serpins 
which are closely related to  PC1 have been expressed,  including 
antithrombin  (42-46),  heparin cofactor I1 (47-491, a,-protein- 
ase  inhibitor (501, a,-anti-chymotrypsin (51),  and  PAI-1(34,52, 
53). Using a baculovirus system, full-length rPCI can be ex- 
pressed in  Sf9 or High-FiveTM cells, and  the recombinant pro- 
tein is fully active. With the exception of incomplete N-glyco- 
sylation, rPCI  was  apparently processed normally by the insect 
cells, and it had  the  same  amino-terminal sequence as plasma 
PCI. rPCI formed bimolecular complexes with proteinases  in a 
manner that was accelerated by heparin. Inhibition of four 
proteinases  (thrombin, APC, urokinase, and  trypsin) showed no 
differences between wt rPCI and plasma PCI. However, the 
amount of heparin  required to maximally  accelerate proteinase 
inhibition by rPCI was  slightly less  than  that of plasma  PCI. 
Although we cannot explain this apparent difference at  the 
present time, it may be due to a reduced glycosylation that 
might result  in slightly better binding of rPCI to heparin. 
Alterations of the P1 reactive site  residue of many  serpins 
strongly influence inhibition activity. a,-Proteinase inhibitor 
Pittsburgh, a natural  mutation of Met358 + Arg, has changed 
its  target  proteinase specificity from elastase  to  thrombin (54). 
Mutation of + Arg in  heparin cofactor I1 resulted  in 
enhanced thrombin but diminished chymotrypsin inhibitory 
activities  (49).  Mutagenesis of the  P1  residue  in PAI-1 showed 
that a basic residue (Lys or Arg) was required for significant 
inhibition of urokinase (34, 53). Our  data confirm the impor- 
tance of the P1 Arg of PC1 in  that  mutation of Ar354 + Met 
displayed  a  significant loss of inhibition  activity  toward pro- 
teinases.  The inhibition profile of R354M rPCI  is very similar  to 
the  a,-proteinase inhibitor, which further  indicates  that a role 
of the P1 residue  is  to resemble a proteinase substrate. Like- 
wise, a,-proteinase  inhibitor  Pittsburgh (P1 Met358 + Arg) is a 
better APC inhibitor than naturally occurring a,-proteinase 
inhibitor (55, 56). Thus, it can be generally concluded that  the 
P1 Arg in PC1 is  important for APC (and  other “trypsin-like’’ 
proteinases) inhibition. 
Using peptidep-nitroanilide  substrates  and chloromethyl ke- 
tone-containing peptide inhibitors,  the specificity of APC for 
the P2 position was found to be large hydrophobic residues like 
Phe  (and Leu), whereas a P2 Gly failed to react (57). Interest- 
ingly, this is the exact difference in the P2-P1-P1’ sequence 
between PC1 (FRS)  and  antithrombin (GRS). Our  study dem- 
onstrated  that changing the  P2  Phe + Gly converted PC1 into 
a better  thrombin  inhibitor which is only 16-fold less  reactive 
than the antithrombin-thrombin reaction in the presence of 
TABLE I 
Proteinase inhibition  rates of rPCI mutants 
Serpinb 
Thrombin (Ha) APC 
Proteinase (k, x M” min”)“ 
IIdAFc Trypsin (T) Urokinase (UK) T/UK 
pPCI  (FRS) 
wt  rPCI  (FRS) 
3.25 f 0.31 x lo7 1.03 k 0.14 x lo6 32 1.02 2 0.18 x lo6 7.83  2.1 x 104 13 
F353G  rPCI  (GRS) 
25 
5.30 0.60 x 
R354M rPCI  (FMS) 
1.34  0.78 x 396 3.17 k 2.2 x 105d 
5.70 f 1.6 x 2.21 1.0 X 1 0 4 d  
2.06 f 0.98 x 1.5 
S355M rPCI  (FRM) 
AT (GRS) 
8.17 1.7 x 33 1.05 f 0.08 x lo6‘ 3.32 k 0.37 x 32 
8.55 f 0.14 x lo8 ~ 1 . 5  x lo1 1.09 2 0.08 x 107 8.59 f 0.53 x lo3 1270 
5.46 f 6.1 x lo4’ 4.84 k 6.5 x lo4‘ 1.1 2.52 5 0.44 x lo6’ 8.96 ? 0.52 x 280 
2.43 0.19 x 107‘ 9.90 -c 3.6 X 105‘ 1.04 k 0.05 x lo6‘ 1.03 k 0.43 x lo5‘ 10 
2.70  0.01 X 107e 
5.39 k 2.4 X 105d 5.68 k 3.1 x 95 2.6 
(Y,-PI (PMS) 
a All proteinase-serpin  inhibition  assays  contained  heparin as detailed  under  “Experimental  Procedures.” 
* Reactive  site  sequence  (P2-P1-P1’)  shown  in  parentheses:  pPCI,  plasma  PCI;  wt  rPCI,  wild-type  rPCI;  F353G  rPCI,  rPCI  with Phe353 + Gly; 
e Not significantly  different from plasma-derived  PCI. 
e Not significantly  different from wt  rPCI. 
f Not significantly  different from R354M rPCI. 
R354M rPCI, rPCI with * Met; and S355M rPCI, rPC1 with Ser355 + Met; AT, antithrombin; a,-PI, a,-proteinase inhibitor. 
Significantly ( p  < 0.05)  different from wt  rPCI. 
16700 Recombinant  Protein C Inhibitor 
optimal heparin.  Furthermore,  there was more than a 7-fold 
reduction in APC inhibition by F353G rPCI compared with PCI. 
F353G rPCI  was also  a better  inhibitor of urokinase,  but it was 
a worse inhibitor of trypsin. A mutant a,-anti-chymotrpysin 
with a P2-P1-P1‘  reactive site sequence of LRS (the wild-type 
sequence is LLS) was recently shown to inhibit APC compa- 
rable with PCI,  further  suggesting  that  hydrophobic P2 resi- 
due  in concert with a P1 Arg is an effective recognition se- 
quence for APC (56). The major conclusion in  our  study 
suggests that a P2 Gly like that found in F353G rPCI  and  in 
antithrombin is not well tolerated for effective APC inhibition, 
but it is excellent for thrombin inhibition. 
One of the most  highly conserved amino acid residues  in  the 
serpin reactive site sequences is the P1’ Ser (7, 8). In some 
instances, as in  antithrombin, it has been found that  the P1‘ 
Ser  is crucial for inhibitory  action possibly due  to hydrophobic 
and size constraints of the reactive site loop (44). In  contrast it 
was found that  all amino acids at the P1’ position, with  the 
exception of Pro, were well tolerated  in PAI-1 (where  the wild- 
type P1‘ is Met) (34). The P1‘ PC1 mutants prepared here 
changed Se?55 + Met or Val and  they showed no substantial 
changes in inhibition activity. Comparing  both  amino acid resi- 
due volumes and hydrophobic indexFs (given in  parentheses) of 
these amino acid residues  (Ser (89 A3, 0.3), Met (163 A3, -1.31, 
and Val (140 A3, -1.5)) show that a variety of possibilities are 
tolerated at  the P1’ position. Our  data  support a concept that 
the P1’ site of PC1 is flexible regarding size constraint and 
hydrophobic character,  and  it may be similar  to PAI-1. 
In summary, we have expressed  recombinant PC1 and  have 
provided some observations about  target  proteinase inhibition 
due to PCI’s reactive site sequence at the P2, P1, and P1‘ 
positions. Interestingly, PC1 is the only serpin  that possesses 
an Arg residue at the  P3‘ position, similar  to fibrinogen, which 
may mediate ionic interactions  with  Gh3’  and G~U’’~ of throm- 
bin (58-60), and G ~ u ” ~  of APC (36). Future PC1 mutagenesis 
studies will examine the  importance of both P3 and P3’ resi- 
dues  in  an  attempt  to  make a PC1 molecule that  has enhanced 
APC but diminished thrombin inhibitory  properties. A better 
understanding of PC1 interactions with its various putative 
plasma target proteinases, especially APC and  thrombin, will 
be useful as new therapeutic  agents  are developed and  tested 
directly dealing  with  the anticoagulation and  anti-inflamma- 
tion  properties of the  protein C  system. 
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